Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial.

Autor:	Huygens S; Department of Internal Medicine, Section of Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands., Hofsink Q; Department of Hematology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands., Nijhof IS; Department of Hematology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine-Hematology, St. Antonius Hospital, Nieuwegein, The Netherlands., Goorhuis A; Department of Infectious Diseases, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands., Kater AP; Department of Hematology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands., Te Boekhorst PAW; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Swaneveld F; Unit of Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands., Novotný VMJ; Unit of Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands., Bogers S; Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands., Welkers MRA; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands., Papageorgiou G; Department of Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands., Rijnders BJ; Department of Internal Medicine, Section of Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands., Heijmans J; Department of Hematology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2023 Jan 11; Vol. 227 (2), pp. 206-210.
DOI:	10.1093/infdis/jiac334
Abstrakt:	Background: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. Methods: Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. Results: Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher's exact test). Conclusions: Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available. Competing Interests: Potential conflicts of interest. F. S. and V. M. J. N. work at Sanquin Blood Supply Foundation. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu